Travere Therapeutics (TVTX) Tops Q1 EPS by $2.43

Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of $1.51, $2.43 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $41.37 million versus the consensus estimate of $44.89 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Constellation Brands (STZ) Tops Q1 EPS by 18c